Vascular endothelial growth factor C promotes survival of retinal vascular endothelial cells via vascular endothelial growth factor receptor-2

British Journal of Ophthalmology

Volumn 91, Issue 4, 2007, Pages 538-545

  Zhao, Bojun ^a,b,c   Smith, Gill ^a,b,c   Cai, Jun ^a,b,c   Ma, Aihua ^a,b,c   Boulton, Mike ^a,b,c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; RECOMBINANT VASCULOTROPIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN C;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFECT; ENDOTHELIUM CELL; FLOW CYTOMETRY; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RETINA BLOOD VESSEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CATTLE; CELL SURVIVAL; CELLS, CULTURED; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HUMANS; PERICYTES; RETINAL VESSELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 34247178963     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.101543     Document Type: Article

References (41)

1. Castellon R, Hamdi HK, Sacerio I, et al. Effects of angiogenic growth factor combinations on retinal endothelial cells. Exp Eye Res 2002;74:523-35.
2. Khaliq A, Foreman D, Ahmed A, et al. Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab Invest 1998;78:109-16.
3. Cai J, Ahmad S, Jiang WG, et al. Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. Diabetes 2003;52:2959-68.
4. Lee J, Gray A, Yuan J, et al. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 1996;93:1988-92.
5. Joukov V, Sorsa T, Kumar V, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. Embo J 1997;16:3898-911.
6. Pepper MS, Mandriota SJ, Jeltsch M, et al. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J Cell Physiol 1998;177:439-52.
7. Witzenbichler B, Asahara T, Murohara T, et al. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol 1998;153:381-94.
8. Cao Y, Linden P, Farnebo J, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA 1998;95:14389-94.
9. Clarijs R, Schalkwijk L, Hofmann UB, et al. Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma. Cancer Res 2002;62:7059-65.
10. Skobe M, Hamberg LM, Hawighorst T, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 2001;159:893-903.
11. Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999;154:1381-90.
12. Meyer M, Clauss M, Lepple-Wienhues A, et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 1999;18:363-74.
13. Dumont DJ, Jussila L, Taipale J, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998;282:946-9.
14. Smith G, McLeod D, Foreman D, et al. Immunolocalisation of the VEGF receptors FLT-1, KDR, and FLT-4 in diabetic retinopathy. Br J Ophthalmol 1999;83:486-94.
15. Witmer AN, Blaauwgeers HG, Weich HA, et al. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci 2002;43:849-57.
16. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 2002;86:363-5.
17. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002;16:438-40.
18. Armstrong D, Augustin AJ, Spengler R, et al. Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica 1998;212:410-14.
19. Limb GA, Chignell AH, Green W, et al. Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 1996;80:168- 73.
20. Spranger J, Meyer-Schwickerath R, Klein M, et al. TNF-alpha level in the vitreous body. Increase in neovascular eye diseases and proliferative diabetic retinopathy. Med Klin 1995;90:134-7.
21. Majka S, McGuire PG, Das A. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization. Invest Ophthalmol Vis Sci 2002;43:260-6.
22. Cogan DG, Toussaint D, Kuwabara T. Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol 1961;66:366-78.
23. Wolffenbuttel BH, Giordano D, Founds HW, et al. Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet 1996;347:513-15.
24. Zhao B, Cai J, Boulton M. Expression of placenta growth factor is regulated by both VEGF and hyperglycaemia via VEGFR-2. Microvasc Res 2004;68:239-46.
25. Wong HC, Boulton M, Marshall J, et al. Growth of retinal capillary endothelia using pericyte conditioned medium. Invest Ophthalmol Vis Sci 1987;28:1767-75.
26. Berisha B, Schams D, Kosmann M, et al. Expression and localisation of vascular endothelial growth factor and basic fibroblast growth factor during the final growth of bovine ovarian follicles. J Endocrinol 2000;167:371-82.
27. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997;276: 1423-5.
28. Tsurusaki T, Kanda S, Sakai H, et al. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer 1999;80:309-13.
29. Kubo H, Fujiwara T, Jussila L, et al. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 2000;96:546-53.
30. Takeshita S, Tsurumi Y, Couffinahl T, et al. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab Invest 1996;75:487-501.
31. Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994;93:662-70.
32. Takagi H, King GL, Aiello LP. Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes. Diabetes 1996;45:1016-23.
33. Yamagishi S, Yonekura H, Yamamoto Y, et al. Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions. Lab Invest 1999;79:501-9.
34. Fajardo LF, Kwan HH, Kowalski J, et al. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol 1992;140:539- 44.
35. Frater-Schroder M, Risau W, Hallmann R, et al. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987;84:5277- 81.
36. Leibovich SJ, Polverini PJ, Shepard HM, et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 1987;329:630-2.
37. Montrucchio G, Lupia E, Battaglia E, et al. Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J Exp Med 1994;180:377-82.
38. Shanmugam N, Reddy MA, Guha M, et al. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003;52:1256-64.
39. Vlassara H, Brownlee M, Manogue KR, et al. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988;240:1546-8.
40. Bussolino F, Camussi G, Baglioni C. Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha. J Biol Chem 1988;263:11856-61.
41. Okamura K, Sato Y, Matsuda T, et al. Endogenous basic fibroblast growth factor-dependent induction of collagenase and interleukin-6 in tumor necrosis factor-treated human microvascular endothelial cells. J Biol Chem 1991;266:19162-5.